Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579405478> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2579405478 endingPage "665" @default.
- W2579405478 startingPage "662" @default.
- W2579405478 abstract "Panel reactive antibody (PRA) reduction protocols are used to decrease anti-HLA antibodies with concomitant PRA monitoring as a measure of successful treatment prior to organ and haploidentical blood and marrow transplant (BMT). We hypothesized that the more sensitive flow cytometry (FC) based assays for PRA [FlowPRA® and Luminex® based Single Antigen Bead (SAB)] would also correlate with the ability to find compatible platelets for allosensitized recipients.A female patient with myelodysplastic syndrome and a high HLA class I PRA [>90% PRA and cPRA by complement-dependent cytotoxicity (CDC) assay and Flow PRA] required allogeneic BMT. Baseline HLA Class I and class II antigen typing was performed and a matched sibling donor was identified. Although baseline anti-HLA class I and class II antibodies measured by FC and CDC revealed no donor specific antibodies (DSA), the decision was made to attempt antibody desensitization to facilitate platelet transfusion during BMT. FC and CDC assays were performed to determine anti-HLA class I antibodies and cPRA/%PRA prior to starting desensitization and at the end of desensitization. Over the course of desensitization and BMT, a total of 194 apheresis platelet units underwent cross-match (XM) using Capture-P®. We compared temporally-related PRA results with platelet XM results.High PRA by FC or CDC assays correlates with a high % of XM-positive (incompatible) platelet units. When the CDC PRA fell to 2% after desensitization, platelet XM incompatibility fell from 100% to 63% positive (incompatible). When the FC PRA fell to 5% the positive platelet XM fell to 5%.Antibody desensitization facilitated platelet transfusion. PRA determination by FC appeared better correlated than determination by CDC with the ability to find XM-compatible platelets." @default.
- W2579405478 created "2017-01-26" @default.
- W2579405478 creator A5033058198 @default.
- W2579405478 creator A5045374912 @default.
- W2579405478 creator A5048028937 @default.
- W2579405478 creator A5080169097 @default.
- W2579405478 creator A5083397819 @default.
- W2579405478 date "2016-12-01" @default.
- W2579405478 modified "2023-10-16" @default.
- W2579405478 title "Flow Cytometric Panel-Reactive Antibody Results and the Ability to Find Transfusion-Compatible Platelets after Antibody-Desensitization for Allogeneic Bone Marrow Transplant." @default.
- W2579405478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27993881" @default.
- W2579405478 hasPublicationYear "2016" @default.
- W2579405478 type Work @default.
- W2579405478 sameAs 2579405478 @default.
- W2579405478 citedByCount "1" @default.
- W2579405478 countsByYear W25794054782023 @default.
- W2579405478 crossrefType "journal-article" @default.
- W2579405478 hasAuthorship W2579405478A5033058198 @default.
- W2579405478 hasAuthorship W2579405478A5045374912 @default.
- W2579405478 hasAuthorship W2579405478A5048028937 @default.
- W2579405478 hasAuthorship W2579405478A5080169097 @default.
- W2579405478 hasAuthorship W2579405478A5083397819 @default.
- W2579405478 hasConcept C126322002 @default.
- W2579405478 hasConcept C147483822 @default.
- W2579405478 hasConcept C159654299 @default.
- W2579405478 hasConcept C170493617 @default.
- W2579405478 hasConcept C188280979 @default.
- W2579405478 hasConcept C203014093 @default.
- W2579405478 hasConcept C2776689292 @default.
- W2579405478 hasConcept C2776738589 @default.
- W2579405478 hasConcept C2777726029 @default.
- W2579405478 hasConcept C2779779143 @default.
- W2579405478 hasConcept C2779867487 @default.
- W2579405478 hasConcept C2909478873 @default.
- W2579405478 hasConcept C40677261 @default.
- W2579405478 hasConcept C542903549 @default.
- W2579405478 hasConcept C553184892 @default.
- W2579405478 hasConcept C64518967 @default.
- W2579405478 hasConcept C71924100 @default.
- W2579405478 hasConcept C89560881 @default.
- W2579405478 hasConceptScore W2579405478C126322002 @default.
- W2579405478 hasConceptScore W2579405478C147483822 @default.
- W2579405478 hasConceptScore W2579405478C159654299 @default.
- W2579405478 hasConceptScore W2579405478C170493617 @default.
- W2579405478 hasConceptScore W2579405478C188280979 @default.
- W2579405478 hasConceptScore W2579405478C203014093 @default.
- W2579405478 hasConceptScore W2579405478C2776689292 @default.
- W2579405478 hasConceptScore W2579405478C2776738589 @default.
- W2579405478 hasConceptScore W2579405478C2777726029 @default.
- W2579405478 hasConceptScore W2579405478C2779779143 @default.
- W2579405478 hasConceptScore W2579405478C2779867487 @default.
- W2579405478 hasConceptScore W2579405478C2909478873 @default.
- W2579405478 hasConceptScore W2579405478C40677261 @default.
- W2579405478 hasConceptScore W2579405478C542903549 @default.
- W2579405478 hasConceptScore W2579405478C553184892 @default.
- W2579405478 hasConceptScore W2579405478C64518967 @default.
- W2579405478 hasConceptScore W2579405478C71924100 @default.
- W2579405478 hasConceptScore W2579405478C89560881 @default.
- W2579405478 hasIssue "6" @default.
- W2579405478 hasLocation W25794054781 @default.
- W2579405478 hasOpenAccess W2579405478 @default.
- W2579405478 hasPrimaryLocation W25794054781 @default.
- W2579405478 hasRelatedWork W1972624436 @default.
- W2579405478 hasRelatedWork W2015337721 @default.
- W2579405478 hasRelatedWork W2040458820 @default.
- W2579405478 hasRelatedWork W2085541012 @default.
- W2579405478 hasRelatedWork W2091852370 @default.
- W2579405478 hasRelatedWork W2462906050 @default.
- W2579405478 hasRelatedWork W2579405478 @default.
- W2579405478 hasRelatedWork W2614283672 @default.
- W2579405478 hasRelatedWork W3214917081 @default.
- W2579405478 hasRelatedWork W4251293782 @default.
- W2579405478 hasVolume "46" @default.
- W2579405478 isParatext "false" @default.
- W2579405478 isRetracted "false" @default.
- W2579405478 magId "2579405478" @default.
- W2579405478 workType "article" @default.